Key result
Current AF and AFL management requires individualized anticoagulation and rhythm or rate control to prevent stroke.
Why the study?
Despite constantly updating knowledge on atrial fibrillation and flutter, questions and doubts remain regarding the nature and extent of their arrhythmic and non-arrhythmic consequences.
This review provides a comprehensive overview of current therapeutic strategies for atrial fibrillation and flutter, emphasizing individualized approaches to anticoagulation and rhythm management.
Answers are grounded in this paper and cite their sources.
Individualized AF strategies remain essential for stroke prevention; confirms consensus while leaving open optimal personalization trials.
Despite constantly updating our knowledge on atrial fibrillation and flutter there are many questions and doubts about the nature and extent of arrhythmic and non-arrhythmic consequences of these arrhythmias. In part 1 of the state-of-the-art paper the diagnostic work-up of patients with the 2 arrhythmias was summarized. The management of patients with atrial fibrillation and flutter requires a multidisciplinary approach in the risk assessment (including stroke) and treatment strategy. Regardless of the type of antiarrhythmic or anticoagulant therapy, benefits must always surpass or at least offset potential adverse effects and drug toxicity. In part 2 of the state-of-the-art paper, current therapeutic strategies have been summarized.
No takes yet. Share an insight, caveat, or question.
Janion−Sadowska et al. (2021) conducted a review in Atrial fibrillation and atrial flutter. Current therapeutic strategies for atrial fibrillation and flutter require individualized anticoagulation and rhythm or rate control to prevent stroke and manage symptoms.
Synapse has enriched 10 related papers. Consider them for comparative context: